Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future.

Ceci, C., Lacal, P.m., Tentori, L., De Martino, M.g., Miano, R., Graziani, G. (2018). Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. NUTRIENTS, 10(11), 1756 [10.3390/nu10111756].

Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid

Ceci C.;Tentori L.;Miano R.
Membro del Collaboration Group
;
Graziani G.
2018-01-01

Abstract

Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future.
2018
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14 - FARMACOLOGIA
Settore MED/24 - UROLOGIA
English
angiogenesis; bladder cancer; breast cancer; colorectal cancer; melanoma; metastases; non-small cell lung cancer (NSCLC); ovarian cancer; polyphenolic compounds; prostate cancer; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Ellagic Acid
Ceci, C., Lacal, P.m., Tentori, L., De Martino, M.g., Miano, R., Graziani, G. (2018). Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. NUTRIENTS, 10(11), 1756 [10.3390/nu10111756].
Ceci, C; Lacal, Pm; Tentori, L; De Martino, Mg; Miano, R; Graziani, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
nutrients-10-01756.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 701.98 kB
Formato Adobe PDF
701.98 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/210674
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 166
  • ???jsp.display-item.citation.isi??? 157
social impact